ENTITY
SciClone Pharmaceuticals

SciClone Pharmaceuticals (SCICLONE HK)

108
Analysis
Health Care • China
SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.
more
•22 Apr 2024 00:17

Merger Arb Mondays (22 Apr) - Shinko, Inageya, C&F Logistics, Hollysys, Azure, Qantm IP, Tietto

This week, the highest gross spreads are Qantm IP (17.6%), Southern Cross (12.6%), Azure (8.8%), QV Equities (8.7%), Hollysys (7.9%), Shinko...

Logo
678 Views
Share
•21 Apr 2024 10:05

Hong Kong Connect Flows (Apr 19th): China Mobile, Bank Of China, Tencent, Petrochina, HSBC

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for China Mobile, Bank Of China, Tencent, Petrochina, ICBC, HSBC.

Logo
579 Views
Share
bullish•Lynas Corp Ltd
•20 Apr 2024 15:00

(Mostly) Asia-Pac M&A: Lynas, Tietto Minerals, JSR, Shinko Electric, TDCX

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
753 Views
Share
•17 Apr 2024 18:10

Hollysys (HOLI US): This Is A Buy

Trading wide at a gross spread of 7.4% to the US$26.50 Offer terms.  Take advantage of investor fatigue, and buy HOLI here.

Logo
618 Views
Share
•17 Apr 2024 02:14

Hollysys (HOLI US): Keep Calm as Closing Date Slips

The spread has widened to 8% due to regulatory approval concerns. Regulatory approval should be forthcoming as the transaction involves Chinese...

Logo
677 Views
Share
x